Zealand names former Lilly exec Singh as CSO
Plus: Changes at Halda, Calidi, Creyon, Aurion, Protalix, Theradaptive and Boston Scientific
Zealand Pharma A/S (CSE:ZEAL) hired Utpal Singh as CSO, with responsibility to lead discovery and development of next-generation peptide therapeutics. Singh was most recently SVP of small molecule discovery at Eli Lilly and Co. (NYSE:LLY), where he spent more than 18 years.
As Halda Therapeutics LLC begins its first clinical study, the biotech has named Eyal Attar CMO. Attar was CMO of Vor Biopharma Inc. (NASDAQ:VOR). New Haven, Conn.-based Halda is enrolling patients in a Phase I/II trial of HLD-0915 to treat prostate cancer; the therapy is based on its Regulated Induced Proximity Targeting Chimeras (RIPTACs) platform, which uses a hold-and-kill mechanism to induce cancer cell death...